Compare Amgen, Inc. (AMGN) vs Raytheon Technologies Corp (RTX) Price & Performance

Amgen, Inc.Trade

Raytheon Technologies CorpTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Raytheon Technologies Corp — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Raytheon Technologies Corp trades at $223.28 (market cap $301.71B). The key difference: Raytheon Technologies Corp is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.

	AMGN	RTX
Market Cap	$224.14B	$301.71B
Sector	Health	Industrials
52-Week High	$417.20	$224.12
52-Week Low	$271.18	$151.75
Enterprise Value	$267.45B	$332.26B
Dividend Yield	2.43%	1.3%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

No Aura AI signal available yet.

Raytheon Technologies Corp

RTX trades at $223.86, up 0.37% today, with a bullish technical signal and strong analyst consensus of 17 buys and a $233.14 price target. Recent earnings beats and a $515 million Navy radar contract (PRNewsWire, June 3, 2026) highlight operational momentum. Revenue grew to $88.60 billion in 2025, with net income margin improving to 8.28%, though a P/E of 39.46 suggests premium valuation.

The outlook is positive, driven by defense contract wins and earnings growth, but risks include high valuation and geopolitical dependencies. Cash flow trends show strengthening operations, supporting dividend payments and strategic investments.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMGN

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

RTX

U.S. Army awards $472M contract to Collins Aerospace for CH-47 Chinook avionics upgradesPRNewsWire · 1 day agoBullish Raytheon wins $745M contract to produce advanced SM-3 IIA missile interceptors for U.S. and alliesPRNewsWire · 2 days agoBullish Raytheon and CET demo HADALUS, a low-cost autonomous undersea vehicle with launch capabilities.PRNewsWire · 2 days agoBullish View details →

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

About Raytheon Technologies Corp

Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.